← Leaderboards
Anthony Charles Faber
Virginia Commonwealth University
$8,190,130
Attributed
$9,327,799
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2014–25$2.5M$1.9M$1.3M$625K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,327,799 · 7
By mechanism
R01$8,627,738 · 5
K22$573,201 · 1
P30$126,860 · 1
Top collaborators
- James A Olzmann6 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Paul Dent$11,860,656
- Arnethea La'shaun Sutton$831,244
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsGrantResearch DesignNovel TherapeuticsMouse ModelClinicCombined Modality TherapyPharmacologic SubstancePre-ClinicalNeuroblastomaMycn GeneMalignant Childhood NeoplasmClinical TrialsPatient Derived Xenograft ModelHigh RiskCancer CellTumorIn VivoCancer TherapyInhibitorCell LineFda ApprovedTranslatingChild
Grant awards (26)
MYCN drives a ferroptotic vulnerability in neuroblastoma$656,289
R01 · FY2025 · CA · contact PI
SUMOylation disruption is toxic for SS18-SSX-driven synovial sarcoma$547,288
R01 · FY2025 · CA · contact PI
ABT-199 based therapies to treat neuroblastoma$492,086
R01 · FY2025 · CA · contact PI
MYCN drives a druggable SUMOylation program in neuroblastoma$429,802
R01 · FY2025 · CA · contact PI
MYCN drives a ferroptotic vulnerability in neuroblastoma$131,820
R01 · FY2025 · CA · contact PI
MYCN drives a ferroptotic vulnerability in neuroblastoma$625,334
R01 · FY2024 · CA · contact PI
SUMOylation disruption is toxic for SS18-SSX-driven synovial sarcoma$525,001
R01 · FY2024 · CA · contact PI
ABT-199 based therapies to treat neuroblastoma$505,898
R01 · FY2024 · CA · contact PI
MYCN drives a druggable SUMOylation program in neuroblastoma$434,312
R01 · FY2024 · CA · contact PI
MYCN drives a ferroptotic vulnerability in neuroblastoma$125,229
R01 · FY2024 · CA · contact PI
Developmental Therapeutics Research Program$63,430
P30 · FY2024 · CA · contact PI
MYCN drives a ferroptotic vulnerability in neuroblastoma$39,941
R01 · FY2024 · CA · contact PI
MYCN drives a ferroptotic vulnerability in neuroblastoma$696,725
R01 · FY2023 · CA · contact PI
SUMOylation disruption is toxic for SS18-SSX-driven synovial sarcoma$571,084
R01 · FY2023 · CA · contact PI
Neuroblastoma reliance on DNMT1 through amplified MYCN$348,032
R01 · FY2023 · CA · contact PI
Developmental Therapeutics Research Program$63,430
P30 · FY2023 · CA · contact PI
Neuroblastoma reliance on DNMT1 through amplified MYCN$348,032
R01 · FY2022 · CA · contact PI
Neuroblastoma reliance on DNMT1 through amplified MYCN$355,134
R01 · FY2021 · CA · contact PI
ABT-199 based therapies to treat neuroblastoma$359,846
R01 · FY2020 · CA · contact PI
Neuroblastoma reliance on DNMT1 through amplified MYCN$355,134
R01 · FY2020 · CA · contact PI
ABT-199 based therapies to treat neuroblastoma$349,049
R01 · FY2019 · CA · contact PI
ABT-199 based therapies to treat neuroblastoma$359,846
R01 · FY2018 · CA · contact PI
ABT-199 based therapies to treat neuroblastoma$371,856
R01 · FY2017 · CA · contact PI
Assessing BIM expression as a cause and marker for resistance to targeted therapi$191,067
K22 · FY2016 · CA · contact PI
Assessing BIM expression as a cause and marker for resistance to targeted therapi$191,067
K22 · FY2015 · CA · contact PI
Assessing BIM expression as a cause and marker for resistance to targeted therapi$191,067
K22 · FY2014 · CA · contact PI